GlassScriptPhysician profile
Shabih U Khan
NPI 1578571063
$4,055.65
in general payments reported to CMS, 2019-2025
21 companies · $434 in 2025
The $434 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,006 · 2020: $726 · 2021: $460 · 2022: $519 · 2023: $459 · 2024: $452 · 2025: $434.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,345.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,344.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,534.88 | 2019-2025 | Xifaxan |
| Amgen INC. | $515.78 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $459.89 | 2019-2023 | Farxiga, Breztri, Fasenra |
| Glaxosmithkline, LLC. | $372.19 | 2019-2023 | Trelegy Ellipta |
| Novo Nordisk INC | $289.88 | 2019-2025 | Rybelsus, Ozempic |
| Amarin Pharma, INC. | $266.95 | 2020-2023 | |
| Abbvie INC. | $94.62 | 2021-2025 | |
| Pfizer INC. | $90.48 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $76.16 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $55.21 | 2019-2021 | |
| Dexcom, INC. | $46.14 | 2022 | |
| Lilly USA, LLC | $43.56 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $40.47 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $37.16 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.69 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $24.45 | 2019 | |
| Vifor Pharma, INC. | $20.08 | 2019 | |
| Xeris Pharmaceuticals, INC. | $19.11 | 2024 | Gvoke Hypopen |
| E.R. Squibb & Sons, L.L.C. | $14.24 | 2025 | Eliquis |
| Astellas Pharma US INC | $14.21 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $11.50 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shabih Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.